Neuroinflammation: Ways in Which the Immune System Affects the Brain

Neurotherapeutics

Volumn 12, Issue 4, 2015, Pages 896-909

  Ransohoff, Richard M ^a   Schafer, Dorothy ^b   Vincent, Angela ^c   Blachère, Nathalie E ^d   Bar Or, Amit ^e  

^a BIOGEN   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ROCKEFELLER UNIVERSITY   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

B cells; Central nervous system; immunology; inflammation; microglial cells; multiple sclerosis; paraneoplastic syndromes

Indexed keywords

AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; B CELL ACTIVATING FACTOR; B LYMPHOCYTE ANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; GLYCINE RECEPTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 35; INTERLEUKIN 6; MATERNAL ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; PROTEIN ANTIBODY; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; TUMOR NECROSIS FACTOR ALPHA; ANTIBODY; CYTOKINE;

ALZHEIMER DISEASE; ANTIBODY MEDIATED ENCEPHALITIS; ARTHROGRYPOSIS; ARTICLE; ASTROCYTE; AUTISM; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL INTERACTION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; EMBRYO DEVELOPMENT; GENE EXPRESSION; GENETIC RISK; HERPES SIMPLEX; HUMAN; HUMORAL IMMUNE DEFICIENCY; HUNTINGTON CHOREA; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; INTERNEURON; LATERAL GENICULATE BODY; MENINGITIS; MICROGLIA; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARANEOPLASTIC NEUROPATHY; PHAGOCYTOSIS; PRIORITY JOURNAL; RELAPSE; RETINA GANGLION CELL; RETT SYNDROME; SCHIZOPHRENIA; STIFF MAN SYNDROME; SYNAPSE; TH17 CELL; THALAMUS; VISUAL CORTEX; ANIMAL; BRAIN; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODIES; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; CYTOKINES; HUMANS; IMMUNE SYSTEM;

EID: 84958185437     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-015-0385-3     Document Type: Article

References (100)

1. Alliot F, Lecain E, Grima B, Pessac B. Microglial progenitors with a high proliferative potential in the embryonic and adult mouse brain. Proc Natl Acad Sci U S A 1991;88:1541–1545.
2. Alliot F, Godin I, Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res 1999;117:145–152.
3. Bilimoria PM, Stevens B. Microglia function during brain development: New insights from animal models. Brain Res 2014.
4. Matyszak MK. Inflammation in the CNS: balance between immunological privilege and immune responses. Prog Neurobiol 1998;56:19–35.
5. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol 2007;28:12–18.
6. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610–621.
7. Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015;523:337–341.
8. Goldmann J, Kwidzinski E, Brandt C, Mahlo J, Richter D, Bechmann I. T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol 2006;80:797–801.
9. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012;12:623–635.
10. Andres KH, von Düring M, Muszynski K, Schmidt RF. Nerve fibres and their terminals of the dura mater encephali of the rat. Anat Embryol (Berl) 1987;175:289–301.
11. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000;343:1020–1034.
12. Leick M, Azcutia V, Newton G, Luscinskas FW. Leukocyte recruitment in inflammation: basic concepts and new mechanistic insights based on new models and microscopic imaging technologies. Cell Tissue Res 2014;355:647–656.
13. Gordon LB, Knopf PM, Cserr HF. Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites. J Neuroimmunol 1992;40:81–87.
14. McKercher SR, Torbett BE, Anderson KL, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J 1996;15:5647–5658.
15. Paloneva J, Manninen T, Christman G, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 2002;71:656–662.
16. Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005;8:752–758.
17. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005;308:1314–1318.
18. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med 2013;368:117–127.
19. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 2013;368:107–116.
20. Guerreiro RJ, Lohmann E, Brás JM, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol 2013;70:78–84.
21. Ueno M, Fujita Y, Tanaka T, et al. Layer V cortical neurons require microglial support for survival during postnatal development. Nat Neurosci 2013;16:543–551.
22. Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011;333:1456–1458.
23. Zhan Y, Paolicelli RC, Sforazzini F, et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci 2014;17:400–406.
24. Parkhurst CN, Yang G, Ninan I, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 2013;155:1596–1609.
25. Katz LC, Shatz CJ. Synaptic activity and the construction of cortical circuits. Science 1996; 274:1133–1138.
26. Hua JY, Smith SJ. Neural activity and the dynamics of central nervous system development. Nat Neurosci 2004; 7:327–332.
27. Sanes JR, Lichtman JW. Development of the vertebrate neuromuscular junction. Annu Rev Neurosci 1999;22:389–442.
28. Del Rio T, Feller MB. Early retinal activity and visual circuit development. Neuron 2006;52:221–222.
29. Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012;74:691–705.
30. Chen C, Regehr WG. Developmental remodeling of the retinogeniculate synapse. Neuron 2000;28:955–966.
31. Hooks BM, Chen C. Vision triggers an experience-dependent sensitive period at the retinogeniculate synapse. J Neurosci 2008;28:4807–4817.
32. Jaubert-Miazza L, Green E, Lo FS, Bui K, Mills J, Guido W. Structural and functional composition of the developing retinogeniculate pathway in the mouse. Vis Neurosci 2005;22:661–676.
33. Ziburkus J, Guido W. Loss of binocular responses and reduced retinal convergence during the period of retinogeniculate axon segregation. J Neurophysiol 2006;96:2775–2784.
34. Huberman AD, Feller MB, Chapman B. Mechanisms underlying development of visual maps and receptive fields. Annu Rev Neurosci 2008;31:479–509.
35. Ackman JB, Crair MC. Role of emergent neural activity in visual map development. Curr Opin Neurobiol 2014;24:166–175.
36. Akiyama H, McGeer PL. Brain microglia constitutively express beta-2 integrins. J Neuroimmunol 1990;30:81–93.
37. Napoli I, Neumann H. Microglial clearance function in health and disease. Neuroscience 2009;158:1030–1038.
38. Perry VH, Hume DA, Gordon S. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain. Neuroscience 1985;15:313–326.
39. Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007;131:1164–1178.
40. Amir RE, van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999;23:185–188.
41. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007;56:422–437.
42. Noutel J, Hong YK, Leu B, Kang E, Chen C. Experience-dependent retinogeniculate synapse remodeling is abnormal in MeCP2-deficient mice. Neuron 2011;70:35–42.
43. Schafer DP, Stevens B. Brains, blood, and guts: MeCP2 regulates microglia, monocytes, and peripheral macrophages. Immunity 2015;42:600–602.
44. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002;2:797–804.
45. Riemersma S, Vincent A, Beeson D, et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest 1996;98:2358–2363.
46. Jacobson L, Polizzi A, Morriss-Kay G, Vincent A. Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice. J Clin Invest 1999;103:1031–1038.
47. Dalton P, Deacon R, Blamire A, et al. Maternal neuronal antibodies associated with autism and a languagedisorder. Ann Neurol 2003;53:533–537.
48. Knuesel I, Chicha L, Britschgi M, et al. Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol 2014;10:643–660.
49. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127:701–712.
50. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011;10:759–772.
51. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133:2734–2748.
52. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:892–900.
53. Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013;136:3151–3162.
54. Lalic T, Pettingill P, Vincent A, Capogna M. Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission. Epilepsia 2011;52:121–131.
55. Ohkawa T, Fukata Y, Yamasaki M, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013;33:18161–18174.
56. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 2012;1:180–187.
57. Waters P, Woodhall M, O'Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015;2:e89.
58. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–1098.
59. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012;54:899–904.
60. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–165.
61. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63–74.
62. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133:1655–1667.
63. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866–5875.
64. Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014;76:108–119.
65. Planagumà J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory andbehaviour in mice. Brain 2015;138:94–109.
66. Wright S, Hashemi K, Stasiak L, et al. Epileptogenic effects of N-methyl-D-aspartate-receptor antibodies in a passive transfer mouse model. Brain 2015;138(11).
67. Hacohen Y, Absoud M, Hemingway C, et al. NMDA receptor antibodies associated with distinct white matter syndromes. Neurol Neuroimmunol Neuroinflamm 2014;1:e2.
68. Leypoldt F, Titulaer MJ, Aguilar E, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology 2013;81:1637–1639.
69. Hacohen Y, Deiva K, Pettingill P, et al. N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord 2014;29:90–96.
70. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008;71:1291–1292.
71. Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 2014;137:2178–2192.
72. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12:554–562.
73. Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 2004;4:36–44.
74. Storstein A, Krossnes BK, Vedeler CA. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand 2009;120:64–67.
75. Amyes E, Curnow J, Stark Z, Corlett L, Sutton I, Vincent A. Restricted IgG1 subclass of anti-Yo antibodies in paraneoplastic cerebellar degeneration. J Neuroimmunol 2001;114:259–264.
76. Tanaka K, Tanaka M, Onodera O, Igarashi S, Miyatake T, Tsuji S. Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J Neurol Sci 1994;127:153–158.
77. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998;4:1321–1324.
78. Blachère NE, Orange DE, Santomasso BD, et al. T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. Eur J Immunol 2014;44:3240–3251.
79. Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006;253:16–20.
80. Orange D, Frank M, Tian S, et al. Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. Arch Neurol 2012;69:113211–40.
81. Lovato L, Willis SN, Rodig SJ, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 2011;134:534–541.
82. Obermeier B, Lovato L, Mentele R, et al. Related B cell clones that populate the CSF and CNS of patients withmultiple sclerosis produce CSF immunoglobulin. J Neuroimmunol 2011;233:245–248.
83. O'Connor KC, Lopez-Amaya C, Gagne D, et al. Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. J Neuroimmunol 2010;223:92–99.
84. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63:395–400.
85. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676–688.
86. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010;74:1860–1867.
87. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779–1787.
88. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons J-A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006;180:63–70.
89. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005;62:258–264.
90. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximabtreatment in multiple sclerosis. Arch Neurol 2010;67:707–714.
91. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naïve human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092–6099.
92. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010;67:452–461.
93. Correale J, Farex M Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol 2008;64:187–199.
94. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2009;5:1001–1010.
95. Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014;507:366–370.
96. Fritz JH, Rojas OL, Simard N, et al. Acquisition of a multifunctional IgA+ plasma cell phenotype in the gut. Nature 2011;481:199–203.
97. Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011;134:2755–2771.
98. Lisak RP, Benjamins JA, Nedelkoska L, et al. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol 2012;246:85–95.
99. Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005;210:195–200.
100. Stern JN, Yaari G, Vander Heiden JA, et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med 2014;6:248ra107.